Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03742349
Title Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

triple-receptor negative breast cancer


Canakinumab + LAG525 + Spartalizumab

LAG525 + MCS110 + Spartalizumab

Capmatinib + LAG525 + Spartalizumab

LAG525 + PBF-509 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.